Medifast (MED) Hisse Özeti
Medifast, Inc. iştirakleri aracılığıyla, Amerika Birleşik Devletleri'nde kilo kaybına yönelik alışkanlık temelli ve koç rehberliğinde yaşam tarzı çözümleri sunan bir sağlık ve zindelik şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Risk Analizi
Risk kontrollerimizden MED için herhangi bir risk tespit edilmedi.
MED Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medifast, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$12.63 |
| 52 Haftanın En Yüksek Seviyesi | US$15.46 |
| 52 Haftanın En Düşük Seviyesi | US$9.22 |
| Beta | 0.57 |
| 1 Aylık Değişim | 14.30% |
| 3 Aylık Değişim | 18.81% |
| 1 Yıllık Değişim | -6.10% |
| 3 Yıllık Değişim | -84.74% |
| 5 Yıllık Değişim | -96.18% |
| Halka arzdan bu yana değişim | 129.64% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Seeking Alpha • May 12
Medifast: Worth Putting On A Watchlist
Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.Recent updates
Anlatı Güncellemesi • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Seeking Alpha • May 12
Medifast: Worth Putting On A Watchlist
Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.Anlatı Güncellemesi • Apr 18
MED: Metabolic Health Initiatives And Insurance Access Will Support Balanced Long-Term Outlook
Analyst price targets for Medifast have been reset, with updated assumptions pointing to a fair value of $12.00 per share. This is now based on a slightly higher discount rate, a similar revenue outlook, a higher profit margin and a lower forward P/E, which analysts cite as the main drivers of the change.Anlatı Güncellemesi • Apr 04
MED: Future Leadership And Metabolic Health Expansion Will Support Long-Term Upside
Analysts have marginally adjusted their price target on Medifast, reflecting slightly higher assumed profit margins and a modestly higher discount rate while keeping fair value at $12. They are framing this as a fine tuning of expectations rather than a major shift in outlook.Anlatı Güncellemesi • Mar 20
MED: Future Leadership Shift Will Seek To Unlock Metabolic Health Opportunity
Analysts have slightly revised their price target on Medifast, with the updated fair value holding at $12.00 as small adjustments to the discount rate and future P/E assumptions refine the underlying model rather than indicate a major change in outlook. What's in the News OPTAVIA’s comprehensive metabolic health system is now eligible for reimbursement on select insurance plans via HSA and FSA funds, which can allow some clients to use pre tax dollars toward program costs (Product related announcement).Anlatı Güncellemesi • Mar 05
MED: Future Leadership Shift Will Align With New Metabolic Health System
Analysts have modestly reduced their price target on Medifast, citing a slightly lower discount rate, a small improvement in projected profit margin, and a shift to a lower future P/E assumption. Together, these factors point to a more cautious valuation framework in dollar terms.Anlatı Güncellemesi • Feb 19
MED: Future Leadership Shift Will Present Long Term Opportunity
Analysts have trimmed their price target for Medifast from $15 to $12, citing updated assumptions that point to softer revenue growth, lower profit margins, and a higher future P/E multiple. What's in the News Medifast issued earnings guidance for the first quarter of 2026, projecting revenue between US$65,000,000 and US$80,000,000 and a loss per share in a range of US$0.15 to US$0.70 (company guidance).Analiz Makalesi • Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) may be sending bullish signals at the...Analiz Makalesi • May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target
It's been a good week for Medifast, Inc. ( NYSE:MED ) shareholders, because the company has just released its latest...Seeking Alpha • Jan 20
Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround
Summary Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a strategy for Medifast to acquire customers who are taking GLP-1s, starting with a collaboration with LifeMD. With a strong balance sheet, but without enough conviction of the success of their strategy, I rate Medifast a Hold. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 09
An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued
Key Insights Medifast's estimated fair value is US$26.41 based on 2 Stage Free Cash Flow to Equity Medifast's US$15.64...Analiz Makalesi • Dec 11
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) is a stock worth checking...
Yeni Anlatı • Nov 10
GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline
The adoption of weight loss medications impacts Medifast's business model, threatening future revenue and customer acquisition.Seeking Alpha • Nov 06
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Summary Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share. Risks include declining coach numbers, competition from GLP-1 medications, and short-selling pressures, but MED's current valuation appears undervalued. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Summary Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are likely to enhance FCF margins. Despite recent lower-than-expected EPS, MED's long-term financial growth and undervaluation suggest strong future stock price potential. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Medifast Business Continues To Shrink, Stock Still Risky
Summary Medifast's stock has plummeted, with dividends still suspended and earnings and revenue are in rapid decline. Despite a strong balance sheet, Medifast faces increased competition and market volatility, leading to a shrinking business. Revenue and earnings are expected to continue declining, making the stock less attractive with higher P/E ratios. Medifast's cash generation has diminished, and the company is focusing on growth rather than dividends, making it a risky investment. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Summary Medifast is a leader in dietary weight management that fell off a cliff since 2022 due to inflationary pressures, the re-opening of restaurants, and the rise of GLP-1 drugs. The company's turnaround plan aims to combine OPTAVIA offerings with direct access to GLP-1 medication through a partnership with LifeMD. At about $20 per share, Medifast may be in deep value territory, but strong negative momentum and the lack of turnaround proof points make it a HOLD at this time. Investors who seek long exposure with an increased margin of safety could consider selling $12.50 MED puts, noting that the company holds over $14 of net cash per share. Read the full article on Seeking AlphaSeeking Alpha • May 24
Medifast: Significant Undervaluation Even As Struggles Persist
Summary Medifast's financial performance is deteriorating rapidly due to the emergence of drug-weight loss competitors. The company reported a significant decline in revenue and earnings in Q1 2023. Medifast is laying off employees and may need to further reduce its workforce to match the revenue drop. My valuation analysis suggests that the stock is significantly undervalued, but I consider this fair given all the challenges. Read the full article on Seeking AlphaAnaliz Makalesi • May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Medifast, Inc. ( NYSE:MED ), might not be a large cap stock, but it received a lot of attention from a substantial...Analiz Makalesi • May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
To the annoyance of some shareholders, Medifast, Inc. ( NYSE:MED ) shares are down a considerable 32% in the last...Analiz Makalesi • May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
Medifast, Inc.'s ( NYSE:MED ) earnings announcement last week didn't impress shareholders. While the headline numbers...Analiz Makalesi • May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Seeking Alpha • Mar 20
Medifast: Cheap Valuation, Uncertain Future
Summary Medifast has had a successful past with continuous growth and strong financial metrics in the health and wellness industry. However, the dynamic nature of the industry raises concerns about the company's future, particularly when considering the recent rise of GLP-1 medications. Investors should consider the implications of industry changes before making a decision on Medifast as an investment. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Medifast Is Getting Attractive
Summary Medifast is experiencing a decline in stock price despite a strong business and consistent cash flow. The company's focus on health and wellness, along with its strategic alliance with LifeMD, positions it for significant upside. Medifast's Optavia solution offers a comprehensive approach to weight loss and has a large addressable market. Shares are a buy with price target of $60. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Unfortunately for some shareholders, the Medifast, Inc. ( NYSE:MED ) share price has dived 26% in the last thirty days...Seeking Alpha • Jan 20
Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Summary Medifast is a weight loss and wellness program that has experienced a significant decrease in market cap and revenue in 2023. The company's business model relies on recruiting coaches to sell their program and products, which has been successful in generating revenue and dividends for investors. However, there are risks associated with supply disruption, market volatility, reputation, and government regulation that could impact the company's future performance. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Key Insights Medifast's estimated fair value is US$140 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Nov 24
Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Summary Medifast has strong financials with a healthy cash position and no debt, but its sales have plummeted, and its business model is questionable. MED's efficiency and profitability metrics are impressive, but its high-priced products may deter customers. The decline in sales can be attributed to tough macroeconomic conditions and competition from weight loss drugs, and the future outlook is uncertain. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Medifast, Inc. ( NYSE:MED ), is not the largest company out there, but it saw significant share price movement during...Seeking Alpha • Nov 09
Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Summary Medifast, Inc. stock is down 80% from its mid-2021 peak, and from a valuation perspective, it looks like a veritable deep-value opportunity. Medifast is currently facing challenges due to elevated consumer price inflation, but increasingly also due to weight loss drugs like Wegovy and soon also Zepbound (or at least their narrative). In this article, I take a look at Medifast's business model, its profitability, and its balance sheet quality against the backdrop of this undoubtedly challenging environment. I also discuss MED's Q3 earnings and whether there is any truth to the theory that GLP-1 receptor agonists pose an existential threat to Medifast's business model. However, I also highlight another potential investment risk that relates to Medifast's most important asset - its coaches. Read the full article on Seeking AlphaHissedar Getirileri
| MED | US Personal Products | US Pazar | |
|---|---|---|---|
| 7D | 0.3% | -2.1% | -0.3% |
| 1Y | -6.1% | -20.0% | 26.7% |
Getiri vs. Endüstri: MED geçen yıl % -20 oranında getiri sağlayan US Personal Products sektörünü aştı.
Getiri vs Piyasa: MED geçen yıl % 26.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 7.8% |
| Personal Products Industry Average Movement | 7.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: MED son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MED 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1980 | 380 | Dan Chard | medifastinc.com |
Medifast, Inc. iştirakleri aracılığıyla, Amerika Birleşik Devletleri'nde kilo kaybına yönelik alışkanlık temelli ve koç rehberliğinde yaşam tarzı çözümleri sunan bir sağlık ve zindelik şirketi olarak faaliyet göstermektedir. Şirket, Essential Fuelings, OPTAVIA ASCEND ve OPTAVIA ACTIVE kategorileri altında barlar, tahıllar, atıştırmalık pipetler, sıcak çikolata, doyurucu seçenekler, yulaf ezmesi, krepler, pudingler, yumuşak servisler, shake'ler, smoothie'ler, yumuşak fırınlar, çorbalar, temel amino asit karışımları, peynir altı suyu proteini, sıcak içecekler, kekler ve mini öğünlerden oluşan kilo verme, kilo yönetimi ve sağlıklı yaşam ürünlerinin yanı sıra multivitaminler, mineraller ve omega-3 yağ asidi takviyeleri dahil olmak üzere günlük besin paketleri sunmaktadır. Ayrıca, güçlü ve hedefe yönelik yağ yakımını etkinleştirerek vücudun metabolizmasının hedefe yönelik olarak sıfırlanmasını sağlayan 5 & 1 Plan ve 5 & 1 ACTIVE Plan; tüm besin gruplarını yemeye devam etmek isteyen veya sağlıklı bir kiloya ulaşmak için esnek bir yemek planı isteyen müşteriler için tasarlanmış Optimal Weight 4 & 2 & 1 Plan ve Optimal Weight 4 & 2 ACTIVE Plan'dan oluşan yaşam tarzı planları da sunmaktadır; Müşterilerin uzun vadeli kilo yönetimine yardımcı olmak için kişiselleştirilmiş bir yaklaşım olan OPTAVIA Optimizasyon Planı; ve müşterilerin ne yiyeceklerini bulma stresi olmadan kilo vermeye odaklanmalarını sağlayan GLP-1 ilacının beslenme arkadaşı olan OPTAVIA GLP-1 Beslenme Destek Planı.
Medifast, Inc. Temel Bilgiler Özeti
| MED temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$129.19m |
| Kazançlar(TTM) | -US$20.02m |
| Gelir(TTM) | US$346.10m |
0.4x
P/S Oranı-6.5x
F/K OranıMED aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MED gelir tablosu (TTM) | |
|---|---|
| Gelir | US$346.10m |
| Gelir Maliyeti | US$103.41m |
| Brüt Kâr | US$242.70m |
| Diğer Giderler | US$262.72m |
| Kazançlar | -US$20.02m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.95 |
| Brüt Marj | 70.12% |
| Net Kâr Marjı | -5.79% |
| Borç/Özkaynak Oranı | 0% |
MED uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 22:08 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Medifast, Inc. 8 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |